ABOUT YolTech

YolTech Therapeutics is a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines. YolTech’s differentiated platform combines innovative gene editing technologies with a proprietary advanced lipid nanoparticle (LNP) delivery system to address a broad range of serious genetic, metabolic and autoimmune diseases.

 
A core pillar of YolTech’s mission is the development of robust internal capabilities, including end-to-end manufacturing, to ensure the highest standards of quality and scalability.

 
YolTech’s growing pipeline includes multiple clinical-stage programs, including YOLT-201, which is being developed for the treatment Transthyretin Amyloidosis (ATTR), YOLT-202 for Alpha-1 Antitrypsin Deficiency (AATD), YOLT-203 for Primary Hyperoxaluria (PH1), YOLT-204 for Beta Thalassemia/Sickle Cell Disease and YOLT-101 for Familial Hypercholesterolemia (FH). As a company dedicated to transforming the treatment landscape, YolTech continues to push the boundaries of what is possible in gene editing.